Engineered immune cells take aim at autoimmune diseases

NCT ID NCT07490951

Recruiting now Disease control Sponsor: Liang Zou Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 28, 2026 · Updated 3 times

Summary

This early study tests a new treatment called CD19/BCMA CAR-T for people with severe autoimmune diseases like lupus and Sjögren's syndrome that haven't improved with standard care. The treatment involves taking a patient's own immune cells, modifying them to target specific immune cells, and infusing them back. The main goals are to check safety and find the right dose, with 20 participants expected.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD19/BCMA-targeted CAR-T cells
What this could lead to: If successful, this could point toward a new treatment option for people with severe autoimmune diseases that haven't responded to standard therapies.
What could go wrong: This is a very early, small trial (20 people) with no control group. CAR-T therapy carries risks like severe immune reactions and infections, and it's unknown if it will work for autoimmune diseases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANCA-ASSOCIATED VASCULITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

antisynthetase syndrome autoimmune disease dermatomyositis granulomatosis with polyangiitis immune-mediated necrotizing myopathy rheumatoid arthritis Sjogren syndrome systemic lupus erythematosus systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE DISEASES

Contacts and locations

Locations

Wuhan No.1 Hospital
NOT_YET_RECRUITING

Wuhan, Hubei, China
Wuhan No.1 Hospital
RECRUITING

Wuhan, Hubei, China
Wuhan No.1 Hospital
RECRUITING

Wuhan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.